Humacyte, Inc.
HUMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1,565 | $1,263 |
| % Growth | – | -100% | 23.9% | – |
| Cost of Goods Sold | $7,190 | $76,550 | $8,255 | $61,341 |
| Gross Profit | -$7,190 | -$76,550 | -$6,690 | -$60,078 |
| % Margin | – | – | -427.5% | -4,756.8% |
| R&D Expenses | $88,599 | $76,550 | $63,260 | $61,341 |
| G&A Expenses | $25,799 | $23,392 | $22,883 | $21,025 |
| SG&A Expenses | $25,799 | $20,390 | $22,883 | $21,130 |
| Sales & Mktg Exp. | $0 | -$3,002 | $0 | $105 |
| Other Operating Expenses | -$7,190 | -$73,443 | -$8,255 | -$61,341 |
| Operating Expenses | $107,208 | $23,497 | $77,888 | $21,130 |
| Operating Income | -$114,398 | -$100,047 | -$84,578 | -$81,208 |
| % Margin | – | – | -5,404.3% | -6,429.8% |
| Other Income/Exp. Net | -$34,303 | -$10,729 | $72,613 | $54,731 |
| Pre-Tax Income | -$148,701 | -$110,776 | -$11,965 | -$26,477 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$148,701 | -$110,776 | -$11,965 | -$26,477 |
| % Margin | – | – | -764.5% | -2,096.4% |
| EPS | -1.26 | -1.07 | -0.12 | -0.66 |
| % Growth | -17.8% | -791.7% | 81.8% | – |
| EPS Diluted | -1.26 | -1.07 | -0.12 | -0.66 |
| Weighted Avg Shares Out | 118,479 | 103,420 | 103,051 | 39,970 |
| Weighted Avg Shares Out Dil | 118,479 | 103,420 | 103,051 | 39,970 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,104 | $5,467 | $2,629 | $16 |
| Interest Expense | $9,277 | $6,599 | $6,200 | $4,348 |
| Depreciation & Amortization | $7,190 | $7,719 | $8,210 | $8,241 |
| EBITDA | -$132,234 | -$96,458 | -$76,368 | -$72,967 |
| % Margin | – | – | -4,879.7% | -5,777.3% |